Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James J Harding

Showing results (111-120 of 138) with videos related to

Pageof 14
Sort By:
Cancer|November 15, 2018
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutationsRaja R Narayan, John M Creasy, Debra A Goldman, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual ConferenceGhassan K Abou-Alfa, Jesper B Andersen, William Chapman, et al.
JCO Precision Oncology|September 16, 2025
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract CancerDarren Cowzer, Madison Darmofal, Kenneth Seier, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
Annals of Surgical Oncology|January 28, 2025
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Annals of Surgical Oncology|January 18, 2025
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Journal of the National Cancer Institute|October 26, 2024
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohortFergus Keane, Catherine O'Connor, Drew Moss, et al.
Pageof 14

Showing results (111-120 of 138) with videos related to

Sort By:
Pageof 14
Cancer|November 15, 2018
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutationsRaja R Narayan, John M Creasy, Debra A Goldman, et al.
The Lancet. Oncology|December 16, 2021
Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trialThomas Yau, Joong-Won Park, Richard S Finn, et al.
Cancer|August 5, 2021
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomesParisa Momtaz, Catherine A O'Connor, Joanne F Chou, et al.
Journal of Gastrointestinal Oncology|January 13, 2017
Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual ConferenceGhassan K Abou-Alfa, Jesper B Andersen, William Chapman, et al.
JCO Precision Oncology|September 16, 2025
Clinical Utility and Prognostic Implications of Circulating Cell-Free DNA in Biliary Tract CancerDarren Cowzer, Madison Darmofal, Kenneth Seier, et al.
JAMA Oncology|September 6, 2019
Assessment of Treatment With Sorafenib Plus Doxorubicin vs Sorafenib Alone in Patients With Advanced Hepatocellular Carcinoma: Phase 3 CALGB 80802 Randomized Clinical TrialGhassan K Abou-Alfa, Qian Shi, Jennifer J Knox, et al.
Nature Communications|February 6, 2023
Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancersJames J Harding, Sarina A Piha-Paul, Ronak H Shah, et al.
Annals of Surgical Oncology|January 28, 2025
ASO Visual Abstract: Adjuvant Cytotoxic Chemotherapy May Not Be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Annals of Surgical Oncology|January 18, 2025
Adjuvant Cytotoxic Chemotherapy may not be Associated with a Survival Advantage for Resected Intrahepatic CholangiocarcinomaJeremy Sharib, Kristen E Rhodin, Annie Liu, et al.
Journal of the National Cancer Institute|October 26, 2024
Adjuvant modified FOLFIRINOX for resected pancreatic adenocarcinoma: clinical insights and genomic features from a large contemporary cohortFergus Keane, Catherine O'Connor, Drew Moss, et al.
Pageof 14